Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.
[2] This drug is being developed by GC Pharma.
As of 2018[update], lenvervimab is undergoing Phase II/III trials.
This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.